HIF-2α-IN-17 is a selective hypoxia-inducible factor 2α ( HIF2α ) inhibitor that binds to the PAS-B domain of HIF2α . HIF-2α-IN-17 disrupts the interaction between HIF2α and the molecular chaperone Hsp70 , leading to proteasomal degradation of HIF2α . HIF-2α-IN-17 exhibits antitumor activity and induces apoptosis in cancer cells. HIF-2α-IN-17 is applicable for research on cancers such as clear cell renal cell carcinoma.
Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > HIF/HIF Prolyl-Hydroxylase | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > HSP | Products > Signaling Pathways > Caspase
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.